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ABSTRACT 110 
Objective: Haptoglobin is a haemoglobin-scavenging protein that binds and neutralises free 111 
haemoglobin and modulates inflammation and endothelial progenitor cell function. A HP gene 112 
copy number variation (CNV) generates HP1 and HP2 allele, the single nucleotide 113 
polymorphism rs2000999 influences their levels. HP1 allele is hypothesized to improve 114 
outcome after intracerebral haemorrhage (ICH). We investigated the associations of the HP 115 
CNV genotype and rs2000999 with haematoma volume, perihaematomal oedema (PHO) 116 
volume, and functional outcome as well as mortality after ICH. 117 
Methods: We included patients with neuroimaging-proven ICH, available DNA, and six-month 118 
follow-up in an observational cohort study (CROMIS-2). We classified patients into three 119 
groups according to the HP CNV: 1-1, 2-1 or 2-2 and also dichotomized HP into HP1-120 
containing genotypes (HP1-1 and HP2-1) and HP2-2 to evaluate the HP1 allele. We measured 121 
ICH and PHO volume on CT; PHO was measured by oedema extension distance. Functional 122 
outcome was assessed by modified Rankin score (unfavourable outcome defined as mRS 3-6). 123 
Results: We included 731 patients (mean age 73.4, 43.5% female). Distribution of HP CNV 124 
genotype was: HP1-1 n=132 (18.1%); HP2-1 n=342 (46.8%); and HP2-2 n=257 (35.2%). In 125 
the multivariable model mortality comparisons between HP groups, HP2-2 as reference, were 126 
as follows: OR HP1-1 0.73, 95%CI 0.34-1.56 (p-value=0.41) and OR HP2-1 0.5, 95%CI 0.28-127 
0.89 (p-value=0.02) (overall p-value=0.06). We found no evidence of association of HP CNV 128 
or rs200999 with functional outcome, ICH volume or PHO volume.   129 
Conclusion: The HP2-1 genotype might be associated with lower 6-month mortality after ICH; 130 
this finding merits further study.  131 
  132 
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INTRODUCTION 133 
Spontaneous (non-traumatic) intracerebral haemorrhage (ICH) is the most devastating form of 134 
stroke with a mortality of about 40% at one month, and 65% at one year1-3. Patients who survive 135 
frequently remain severely disabled4. Moreover, incidence of ICH is increasing in the elderly 136 
population5-7, in part due to increasing use of oral anti-coagulation5-7.  137 
Spontaneous ICH results from bleeding into the brain parenchyma arising from the rupture of 138 
an arterial vessel, most often (>80%) a small arteriole affected by cerebral small vessel diseases 139 
(SVD). The commonest sporadic SVD that cause ICH are deep perforator arteriopathy (also 140 
termed hypertensive arteriopathy or arteriolosclerosis) and cerebral amyloid angiopathy 141 
(CAA). A minority of ICH (less than 20%) is caused by structural or macrovascular bleeding 142 
sources such as tumours, arteriovenous malformations, cavernomas or fistulas. Deep perforator 143 
arteriopathy is associated with hypertension and is a frequent cause of deep ICH; CAA is 144 
caused by amyloid beta deposition in cortical and leptomeningeal blood vessels and is a key 145 
cause of lobar ICH. 146 
Haptoglobin is an acute-phase protein which neutralizes free haemoglobin by binding it, and 147 
in doing so targets haemoglobin to the CD163 receptor for clearance8-15. Haptoglobin prevents 148 
the toxic and inflammatory effects of haemoglobin by shielding its iron-containing pocket, and 149 
preventing its breakdown into haem and iron, which consequently cause cytotoxicity and brain 150 
oedema8-15. The HP gene has a copy number variant (CNV), which leads to two co-dominant 151 
alleles: HP1 and HP2. Three different HP CNV genotypes exist: HP1-1, HP2-1 and HP2-2, 152 
and their respective protein products differ in molecular size and haemoglobin-binding 153 
capacity15-17. A previous study demonstrated some evidence that patients with the HP2 allele 154 
have a larger haematoma volume, though the underlying mechanisms remain unknown18. An 155 
increase in haematoma volume may be accompanied by more perihaematomal oedema 156 
(PHO)18 19. ICH and PHO volume have been demonstrated to influence functional outcome18 157 
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19. A previous study reported worse functional outcome for patients with HP2 allele (HP2-1 or 158 
2-2) compared to HP1-1 patients as well as some evidence for increased mortality for each 159 
HP2 allele18. The HP CNV might be associated with functional outcome after ICH through 160 
differences in haemoglobin clearance and protection from the cytotoxic and inflammatory 161 
effects of haemoglobin breakdown products. However most previous studies investigating 162 
haptoglobin in ICH are based on investigations in rodents.  163 
The single nucleotide polymorphism (SNP) rs2000999 accounts for up to 50% of variation in 164 
circulating haptoglobin levels in the blood independently of the HP CNV20. The combined use 165 
of the HP CNV and rs2000999 has been suggested as an important genetic tool to discriminate 166 
between two potential mechanisms underlying differences between HP1 and HP2 alleles: 167 
haptoglobin expression level and functional differences in haptoglobin protein products21.  168 
We performed a comprehensible multivariable study investigating the influence of the HP 169 
CNV and rs2000999 SNP on functional outcome and mortality after ICH. We also aimed to 170 
assess the influence of the HP CNV and the rs2000999 SNP on ICH volume and OED.  171 
 172 
METHODS 173 
Data collection 174 
We considered patients, of predominantly Caucasian descent, with spontaneous ICH and 175 
available blood samples recruited into the Clinical Relevance of Microbleeds in Stroke ICH 176 
study22. We defined spontaneous ICH as a non-traumatic haemorrhage into the brain 177 
parenchyma, presumed due to cerebral SVD after the exclusion of patients with an underlying 178 
structural or macrovascular cause.  179 
We collected detailed information on demographics, risk factors, medication, clinical 180 
presentation, and radiological data. A diagnosis of hypertension, hypercholesterolaemia and 181 
diabetes mellitus was present if reported by the patient, stated on medical records or if either 182 
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drug treatment or any other form of advice (including lifestyle changes) was given. Smoking 183 
was defined as current and previous use. All patients had acute brain imaging with CT. Written 184 
informed consent was obtained from all participants, or a relative or representative. We 185 
excluded patients <18 years, patients without available or adequate CT scan. Patients with a 186 
CT scan after 72 hours from symptom onset were excluded from the primary ICH and PHO 187 
volume analysis.18 23 24. We classified ICH location into lobar, deep (basal ganglia, thalamus), 188 
cerebellar and brainstem according to a validated rating scale25. Our outcomes were death and 189 
functional outcome at 6 months (measured by the modified Rankin Scale [mRS] dichotomized 190 
into favorable [mRS 0-2] or unfavorable [mRS 3-6] categories).  191 
Haptoglobin genotyping 192 
To determine the HP CNV we optimised a high-throughput qPCR genotyping assay as 193 
described previously26. The assay amplified a region in the 5` terminal of the HP gene’s first 194 
exon as an internal control (HP5`), and the breakpoint of the HP duplication (HP2). The 195 
HP2/HP5` ratio (theoretically either 0, 1, or 2) was used to determine the genotype as HP1-1, 196 
HP2-1 or HP2-2 respectively. Samples were run in triplicates; triplicates with a HP2/HP5`ratio 197 
coefficient of variation >10% were re-assayed. A second method of HP genotyping by PCR27 198 
was performed on samples with HP2/HP5’ ratio values between 0.46-077, in order to confirm 199 
the HP CNV genotype. Rs2000999 was genotyped using Kompetitive Allele Specific PCR 200 
(KASP) assay technology28 (LGC Genomics Limited, Hertfordshire, UK), call rate was 97.3%. 201 
Measurement of ICH and PHO volume 202 
We measured ICH and PHO volume as previously described via a semi-automated, threshold-203 
based approach29. PHO was measured by the oedema extension distance (OED) using a 204 
previously described formula19; the rationale behind using OED is that PHO extends a 205 
consistent mean linear distance from the border of the ICH, independently of its volume. 206 
 207 
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Statistical analysis 208 
We present categorical variables using frequency and percentages, continuous variables using 209 
mean ± standard deviation (SD). We transformed ICH and PHO volume with cube root 210 
transformation to satisfy statistical normal distribution assumptions. We conducted a post hoc 211 
sensitivity analysis comparing patients with ICH volume and OED before and after 72 hours.  212 
We assessed the distribution of the HP CNV and rs2000999 SNP in the CROMIS-2 cohort 213 
compared to ALSPAC (Avon Longitudinal Study of Parents and Children) cohort of healthy 214 
individuals, which we used as controls. ALSPAC is a general population cohort study30 31; HP 215 
genetic data and rs2000999 SNP data was available from 927 and 748 participants. The 216 
ALSPAC study website (http://www.bristol.ac.uk/alspac/researchers/our-data/) contains 217 
details of all the data available through a fully searchable data dictionary and variable search 218 
tool. Ethical approval for the study was obtained from the ALSPAC Ethics and Law Committee 219 
and the Local Research Ethics Committees. To evaluate the HP1 allele, we also assessed the 220 
HP CNV as a dichotomized variable (HP1-1 and HP2-1 versus HP2-2) according to our pre-221 
specified analysis plan.  222 
We first performed univariable analyses for each of the four outcomes separately with 223 
demographic, clinical and radiological variables of interest. We subsequently fitted 224 
multivariable logistic regression models with significant variables from the univariable 225 
analysis in addition to pre-specified variables. For the analysis of ICH and OED volume we 226 
adjusted the models with the pre-specified variables: time from event to imaging, location of 227 
ICH, systolic blood pressure (SBP), HP CNV and rs200999 SNP. For functional outcome and 228 
mortality analysis, we fitted the multivariable model with the pre-specified variables: age, sex, 229 
hypertension, oral anticoagulation (OAC), HP CNV and rs200999 SNP. Additionally, we fitted 230 
the multivariable models with variables that were statistically significant at the 20% level in 231 
the univariable analysis. 232 
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We investigated whether there were interactions between different variables. However, no 233 
interaction reached our pre-specified significant threshold for interactions of p<0.001 (chosen 234 
to guard against overfitting) and were therefore not included in the models32. 235 
Statistical analysis was performed using STATA 15 (StataCorp. 2011. Stata Statistical 236 
Software: Release 15. College Station, TX: StataCorp LP). 237 
 238 
Ethical approval 239 
The CROMIS-2 study was approved by the local Ethics Committee (reference: 10/H0716/64). 240 
 241 
RESULTS 242 
For the primary analysis of functional outcome at 6 months we included 732 patients. One 243 
DNA sample was uncallable for the HP CNV and 20 for the rs2000999 SNP. For the secondary 244 
analyses of ICH volume and PHO we included 709 patients with an available CT scan (Figure 245 
1). OED mas measured at a mean of 10 hours from ICH onset. Patients who were genotyped 246 
(n=844) were not different to those without DNA (n=250) with regard to baseline 247 
characteristics and risk factor profile (data not shown). The rs2000999 genotype frequency in 248 
CROMIS-2 was as expected when compared to ALSPAC (Supplementary Table 1). However, 249 
compared to ALSPAC, CROMIS-2 patients less often had the HP2-2 CNV. We found no 250 
systematic difference in demographics, comorbidities and ICH characteristics between those 251 
with and without available outcome variable (data not shown).  252 
 253 
Mortality  254 
Of 731 patients with available follow-up and genotype data, 112 died within 6 months (15.3%) 255 
and 318 (43.5%) were female.  256 
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The distribution of the HP CNV was 132 HP1-1 (18.1%), 342 HP2-1 (46.8%) and 257 HP2-2 257 
(35.2%). Distribution of the SNP allele was: 27 A:A (3.8%), 234 A:G (32.9%) and 451 G:G 258 
(63.3%), 20 samples were not callable (2.7%). 259 
Patients who died were older, more frequently female, more frequently on OAC, had a lower 260 
GCS on admission (GCS <8), a higher ICH and PHO volume, and intraventricular extension 261 
(IV). Results of the univariable analysis are shown in supplementary Table 2.  262 
The mortality according to HP CNV was as follows: HP1-1 18.2%; HP2-1 12.6%; HP2-2 263 
17.5%. In the multivariable model (n=608) mortality comparisons between the HP groups, 264 
with  HP2-2 as a reference group, were as follows: OR HP1-1 0.73, 95% CI 0.34-1.56 (p-265 
value=0.41) and OR HP2-1 0.5, 95% CI 0.28-0.89 (p-value=0.02) (overall p-value=0.06, Table 266 
1).   267 
  268 
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Table 1:  Factors associated with 6 month mortality after ICH in an adjusted multivariable 269 
logistic regression model 270 
 271 
  
OR 
 
95% CI 
 
P value 
 
 
Age (years) 
1.11 1.07-1.14 <0.001 
    
Female Sex 1.14 0.68-1.92 0.63 
    
Hypertension 1.01 0.57-1.76 0.99 
    
Diabetes mellitus 1.31 0.65-2.65 0.46 
    
Oral anticoagulation 1.25 0.74-2.11 0.4 
    
GCS on admission (binary)    
- GCS 3-8  4.23 1.35-13.28 0.01 
- GCS 9-15 (reference)    
    
ICH location    
- Cerebellar (reference)    
- Brainstem Empty  0.38 
- Deep  0.98 0.33-2.93  
- Lobar 0.64 0.2-2  
    
Cr ICH volume (mL) 2.03 1.48-2.8 <0.001 
    
OED (cm) 2.82 1.01-7.92 0.05 
    
IV extension 1.56 0.89-2.72 0.12 
    
HP CNV   
 
0.06 
- HP1-1 0.73 0.34-1.56  
- HP2-1 0.5 0.28-0.89  
- HP2-2 (reference)    
    
Rs2000999   0.74 
- A:A (reference)    
- A:G 0.6 0.15-2.36  
- G:G 0.58 0.15-2.28  
    
 272 
cm = centimeter; CNV = copy number variation; Cr = cube root; CT = computed 273 
tomography; GCS = Glasgow Coma Scale; HP = Haptoglobin; ICH = intracerebral 274 
haemorrhage; IV = intraventricular; ml = milliliter; OAC: oral anticoagulation; SBP: systolic 275 
blood pressure 276 
 277 
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When dichotomizing HP into HP1-1/2-1 versus HP2-2 there was evidence for association of 278 
decreased mortality with the HP1 allele compared to HP2-2 (OR 0.55, 95%CI 0.31-0.95, 279 
p=0.03, supplementary Table 3). As expected, there was also evidence for an increase in 280 
mortality with increasing age (OR 1.11, 95%CI 1.07-1.14, p<0.001), decreased GCS on 281 
admission <9 (OR 4.37, 95%CI 1.39-13.73, p=0.01), and ICH volume (OR 1.99, 95%CI 1.45-282 
2.74, p<0.001).  283 
 284 
We further investigated the association between mortality and HP CNV across tertiles of all 285 
the covariates included in the multivariable model as a post hoc analysis. Mortality differed 286 
between the HP groups for older patients (>80 years) with lower (<12.2mL) ICH volume: in 287 
this subgroup, mortality was 26% for HP1-1, 14% for HP2-1 and 42% for HP2-2. Patients died 288 
at a median of 3.8 months after ICH. There was no difference (early vs. late death) in the time 289 
of death after ICH across HP CNV or rs2000999 groups, in the overall cohort or the subgroup 290 
of >80 years and <12.2mL ICH volume (regression data not shown, supplementary Figure 1). 291 
The mortality rate was similar across the HP groups for the remaining patients: 15% for HP1-292 
1, 12% for HP2-1 and 12% for HP2-2. The association between mortality and HP CNV was 293 
confirmed across tertiles of all the other covariates. Finally, we investigated covariates not 294 
included in the multivariable model, to see whether they differed across HP genotypes, but 295 
found no bias to explain the association between mortality and HP CNV (data not shown). 296 
 297 
Functional outcome  298 
Of 731 patients, 444 (60.7%) suffered an unfavourable outcome (mRS 3-6). Dichotomized 299 
unfavourable mRS according to HP CNV was as follows: HP1-1 64.4%; HP2-1 59.7%; HP2-300 
2 60.3%.  301 
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Patients with an unfavourable outcome were older, more frequently female, on OAC, more 302 
frequently had hypertension, hypercholesterolaemia, presented with a lower GCS (GCS of 3-303 
8), had a higher ICH and PHO volume and IV extension. See supplementary Table 2 for 304 
univariable analysis.  305 
In the multivariable model (n=623) age (OR 1.04, 1.02-1.06 95%CI; p<0.001), female sex (OR 306 
2.31; 1.58-3.37; 95%CI; p<0.001) and the cube root of the ICH volume (OR 1.5; 1.22-1.85 307 
95%CI; p<0.001) were significantly associated with functional outcome (Table 2). Neither HP 308 
CNV nor rs2000999 SNP were associated with functional outcome.  309 
  310 
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Table 2: Factors associated with unfavourable outcome after ICH in an adjusted multivariable 311 
regression model 312 
 313 
  
OR 
 
95% CI 
 
P value 
 
 
Age (years) 
1.04 1.02-1.06 <0.001 
    
Female Sex 2.31 1.58-3.37 <0.001 
    
Hypertension 1.37 0.92-2.04 0.12 
    
Diabetes mellitus 1.18 0.71-1.97 0.52 
    
Oral anticoagulation 1.16 0.77-1.73 0.49 
    
Antiplatelets 1.08 0.7-1.69 0.72 
    
Hypercholesterolaemia 1.17 0.78-1.75 0.44 
    
GCS on admission (binary)    
- GCS 3-8  3.56 0.76-16.5 0.11 
- GCS 9-15 (reference)    
    
Cr ICH volume (mL) 1.5 1.22-1.85 <0.001 
    
IV extension 1.38 0.9-2.12 0.14 
    
Surgical evacuation 1.84 0.45-7.5 0.39 
    
HP CNV   0.78 
- HP1-1  1.17 0.67-2.03  
- HP2-1 0.97 0.65-1.45  
- HP2-2 (reference)    
    
Rs2000999   0.66 
- A:A (reference)    
- A:G 1.19 0.43-3.3  
- G:G 1.39 0.5-3.84  
    
 314 
 315 
CNV = copy number variant; Cr = cube root; CT = computed tomography; GCS = Glasgow 316 
Coma Scale; HP = Haptoglobin; ICH = intracerebral haemorrhage; IV = intraventricular; ml 317 
= millilitre; OAC: oral anticoagulation; SBP: systolic blood pressure 318 
 319 
 320 
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Intracerebral haemorrhage volume and oedema extension distance 321 
Of the 731 patients included in the functional analysis, 709 had a CT scan available, and of 322 
these 68 were >72 hours after symptom onset (Figure 1).  Of the remaining 641 individuals, 323 
453 (70.7%) had a scan <24h, 172 (26.8%) between 24-48h and 16 (2.5%) between 48-72h. 324 
See Figure 2 for the association of the HP CNV and SNP with OED and ICH volume.  325 
Mean ICH volume was 13.8 mL (± 18.82 SD), mean PHO volume 19.54 mL (± 20.56 SD) and 326 
mean OED 0.51 cm (±0.23 SD). Variables significantly associated with ICH volume in the 327 
univariable analysis are listed in the supplementary Table 3. 328 
In the fitted multivariable model (n=604) ICH location (overall p<0.001) and intraventricular 329 
extension (coefficient 0.53; 0.37-0.68; p<0.001) were associated with greater ICH volume 330 
(Table 3). Neither HP CNV nor the SNP rs2000999 were associated with ICH volume.  331 
  332 
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Table 3:  Factors associated with the cube root ICH volume in an adjusted multivariable 333 
regression model  334 
 335 
 Coefficient 95% CI 
 
P value 
 
    
Age (years) -0.005 -0.01-0.001 0.09 
    
Time Event to CT   0.35 
- Day 1 (reference)    
- Day 2 0.04 -0.23-0.31  
- Day 3 -0.29 -0.7-0.11  
    
ICH location   <0.001 
- Cerebellar (reference)    
- Brainstem -0.73 -1.22-0.23  
- Deep -0.13 -0.44-0.18  
- Lobar 0.79 0.47-1.1  
SBP (mmHg) 0.001 -0.002-0.002 
0.88 
 
Platelet level (x109/liter) 0.001 -0.0004-0.001 0.31 
    
Hypercholesterolaemia 0.09 -0.05-0.22 0.2 
    
IV extension 0.53 0.37-0.68 <0.001 
    
Neurosurgery 0.36 -0.06-0.78 0.1 
 
HP CNV 
  
 
 
0.66 
- HP1-1 -0.09 -0.25-0.52  
- HP2-1 -0.02 -0.17-0.13  
- HP2-2 (reference)    
    
Rs2000999   0.68 
- A:A (reference)    
- A:G 0.14 -0.25-0.52  
- G:G 0.16 -0.22-0.54  
    
 336 
CNV = copy number variation; CT = computed tomography; HP = Haptoglobin; ICH = 337 
intracerebral haemorrhage; IV= intraventricular; mmHg = millimetre mercury; SBP= systolic 338 
blood pressure 339 
 340 
 341 
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After dichotomizing the HP CNV into HP1-1/2-1 versus HP2-2 we did not observe any 342 
evidence of an association in univariable or multivariable analyses (p = 0.39 [supplementary 343 
Table 4] and p = 0.6 respectively [data not shown]). Similar results were observed when 344 
dichotomizing HP CNV into HP1-1 versus HP2-1/2-2 [supplementary Table 4]. 345 
 346 
Oedema Extension Distance  347 
Variables significantly associated with OED in the univariable analysis are listed in 348 
supplementary Table 4. For comparison of HP CNV and SNP for ICH volume and OED see 349 
Figure 2.  350 
In the multivariable linear regression model (n=623), ICH location (with lobar and deep ICH 351 
locations featuring a longer OED and with a brainstem location featuring a shorter OED, 352 
compared to the reference group of cerebellar location, overall p<0.001) and antihypertensive 353 
medication (coefficient -0.09; 95%CI -0.16-(-0.02); p=0.01) were significantly associated with 354 
OED (Table 4). Neither the univariable nor multivariable analysis showed evidence of 355 
association of HP CNV or rs2000999 SNP with OED.  356 
Similar to the ICH volume model, dichotomizing HP did not yield any evidence of association 357 
in univariable and multivariable models (data not shown).  358 
  359 
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Table 4:  Factors associated with size of oedema extension distance in an adjusted 360 
multivariable regression model  361 
 362 
  
Coefficient 
 
95% CI 
 
P value 
 
    
Female Sex 0.01 -0.02-0.05 0.44 
    
Time Event to CT   0.18 
- Day 1 (reference)    
- Day 2 0.07 -0.008-0.14  
- Day 3 0.04 -0.07-0.15  
    
ICH location   
 
<0.001 
- Cerebellar (reference)    
- Brainstem -0.08 -0.21-0.06  
- Deep 0.16 0.07-0.24  
- Lobar 0.24 0.15-0.33  
 
SBP (mmHg) 
 
0.0002 
 
-0.0003-0.001 
 
0.49 
    
OAC 0.05 -0.02-0.12 0.17 
    
Antihypertensive medication -0.09 -0.16-(-0.02) 0.01 
    
Platelet level (x109/liter) 0.0002 -0.00005-0.0004 0.11 
    
IV extension -0.03 -0.07-0.008 0.11 
HP CNV   
 
0.5 
- HP1-1  0.03 -0.02-0.09  
- HP2-1 0.01 -0.03-0.05  
- HP2-2 (reference)    
    
Rs2000999   0.93 
- A:A (reference)    
- A:G 0.01 -0.09-0.11  
- G:G 0.003 -0.1-0.1  
    
 363 
CNV = copy number variation; CT = computed tomography; HP = Haptoglobin; ICH = 364 
intracerebral haemorrhage; mmHg = millimetre mercury; OAC: oral anticoagulation; SBP: 365 
systolic blood pressure 366 
 367 
 368 
 369 
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DISCUSSION 370 
In this large prospective, multicentre cohort study, HP was not associated with functional 371 
outcome as assessed by the mRS. The HP CNV distribution was comparable to that reported 372 
in a previous study, apart from a slightly higher proportion of HP1-1 patients and lower 373 
proportion of HP2-218. Despite the larger sample size, we could not replicate this previous 374 
study’s finding of an association of the HP2 allele with functional outcome18. 375 
 376 
However, we found evidence that mortality was lower in HP2-1 patients compared to HP2-2 377 
homozygotes; our post hoc analyses suggest that this observation is mostly driven by older 378 
patients with lower ICH volumes. No association with mortality was found for the rs2000999 379 
SNP (which is associated with haptoglobin expression level)21. This suggests that any link 380 
between the HP CNV and mortality is mediated by factors other than haptoglobin expression.  381 
 382 
While the HP CNV’s association with mortality could have been confounded by bias in a 383 
variable excluded from the model, we did not find any evidence for this. Such a factor could 384 
still remain unidentified, but a more likely explanation is that patients who died did not 385 
contribute to functional outcome analysis. We found evidence of HP2-2 missingness (of 386 
subjects of a particular genotype, in this case HP2-2), when comparing CROMIS-2 with 387 
ALSPAC cohorts, which might suggest that the HP2-2 genotype confers a mortality risk. 388 
 389 
We confirmed previous results showing evidence towards increased mortality with HP2-218, 390 
but did not observe a unidirectional dose response of HP alleles in a direction of increasing or 391 
decreasing mortality across HP genotypes (mortality: HP1-1 18.2%; HP2-1 12.6%; HP2-2 392 
17.5%). The lower mortality in HP2-1 individuals could be a chance finding. A possible but 393 
unlikely explanation is heterozygote advantage or heterosis33. At a molecular level, the HP1 394 
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allele might protect against the deleterious effect of the HP2 allele only when the two alleles 395 
are present together in HP2-1 individuals. Both HP1 and HP2 alleles scavenge haemoglobin, 396 
with HP2 being superior34 35, and this confers a beneficial effect. However, HP2 has additional 397 
off-target effects which are deleterious, mostly pro-inflammatory36. In HP2-2 individuals, the 398 
better haemoglobin scavenging potential of HP2 versus HP1 is offset by its proinflammatory 399 
effects, so that mortality is similar in HP1-1 and HP2-2 individuals. In HP2-1 individuals, the 400 
HP1 allele may be negating the deleterious effect of HP2, so that a greater benefit is observed 401 
in HP2-1 individuals than is expected by simple co-dominance of the two alleles.  402 
 403 
We did not confirm previous findings of worse functional outcome in patients with HP2 allele, 404 
which could be due to the significantly smaller cohort size and statistical power of the previous 405 
study, with potential for a chance finding18.  406 
 407 
PHO develops over a continuous period of time in three main stages. It peaks after two weeks, 408 
however its evolution is most rapid in the first 2-3 days37. PHO is thought to be mediated by a 409 
process of toxicity and inflammation19 37. We hypothesized that by modulating neurotoxicity 410 
and inflammatory processes haptoglobin might have influenced PHO and functional 411 
outcome.38 However, we did not find any association of HP genetic variants (CNV or the 412 
rs2000999 SNP) with OED. Similarly, HP genetic variants were not associated with ICH 413 
volume, which, like haemtoma expansion, is more likely to be driven by other factors including 414 
hydrostatic pressure at the bleeding point18.  415 
 416 
Despite having a large cohort available, we could not replicate the previous study’s reported 417 
finding of an association of the HP2 allele with larger ICH volumes and IV extension 18. Since 418 
ICH volume and OED was assessed on CT scans performed within 72 hours of symptom onset, 419 
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we cannot exclude an association of HP with ICH volume or OED after this timepoint, although 420 
our exploratory analysis of scans beyond 72 hours (n=68) and found no difference in ICH 421 
volume and OED across HP genotypes (for both CNV and rs2000999 SNP) (data not shown).  422 
We found that long-term antihypertensive medication prior to ICH event is independently 423 
associated with decreased OED, even after correcting for SBP. It is possible that patients on 424 
antihypertensive medication could have reduced sympathetic activity and inflammatory 425 
response when ICH occurs39, a hypothesis that merits further study. As we did not collect 426 
follow-up scans, we cannot comment on a potential influence of SBP on haematoma growth. 427 
 428 
Our study has strengths. Our prospective, multi-centre study is the largest on HP and ICH to 429 
date, and should be generalizable to Caucasian populations. We collected detailed baseline 430 
clinical and brain imaging data and undertook multivariable regression analysis adjusting and 431 
correcting for important predictors of all four outcomes, and took exceptional care to control 432 
for covariates.  433 
 434 
However, our study also has limitations. Since we obtained informed or proxy consent, our 435 
study is biased towards ICH survivors with less severe ICH than would be included in an 436 
unselected incident ICH population. However, it is likely that any protective effect of HP is 437 
most relevant in ICH patients who survive the acute period. Additionally, CT scans at multiple 438 
timepoints were not available and therefore we could not assess the influence of HP CNV and 439 
rs200999 SNP on ICH, PHO or OED expansion over time. We also did not have data on the 440 
time interval between the ICH and CT scan. However, in a post hoc sensitivity analysis ICH 441 
volume before and after 72 hours was very similar although OED was larger in patients with 442 
first imaging after 72 hours. As PHO increases beyond 72 hours further studies are needed to 443 
assess an influence of the HP CNV and rs2000999 SNP on oedema expansion. Although we 444 
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excluded patients without blood samples available for genetic analysis, there were no 445 
systematic differences in demographics, comorbidities and ICH characteristics between those 446 
with and without genetic data available.  Finally, it would have been interesting to study plasma 447 
and cerebrospinal fluid haptoglobin levels in relation to HP genetic variants, but unfortunately 448 
these were not available.  449 
 450 
CONCLUSION 451 
We investigated the association of HP genetic variation (the HP CNV and the rs2000999 SNP) 452 
in a large cohort of 731 ICH patients. We found evidence in support of a lower mortality with 453 
the HP2-1 genotype, but not functional outcome, ICH volume or OED. While HP genotype 454 
may not matter for functional outcome, upregulating or supplementing haptoglobin may still 455 
be of benefit, as demonstrated in animal studies40, so understanding how different haptoglobin 456 
types associate with outcome is important. A future meta-analysis may be appropriate to 457 
confirm our observations, and longer follow-up may be needed in case there is an association 458 
with longer term outcome. 459 
 460 
  461 
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FIGURE LEGENDS 597 
Figure 1. Patient selection flow diagram  598 
Figure 2. A) Differences in OED in Haptoglobin genotype and SNP, B) Differences in ICH 599 
volume in Haptoglobin genotype and SNP 600 
Supplementary Figure 1. A) Time to death in days by HP CNV overall cohort, B) Time to death 601 
in days by rs2000999 overall cohort, C) Time to death in day by HP CNV subgroup >80 years 602 
<12.2mL ICH volume, D) Time to death in day by rs2000999 subgroup >80 years <12.2mL 603 
ICH volume 604 
